AMPA is a type of receptor in your brain that handles the majority of fast signaling between nerve cells. Its full name, alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid, describes the chemical used to identify it in the lab, but what matters is what it does: AMPA receptors are the workhorses of brain communication, opening and closing in less than a millisecond to pass electrical signals from one neuron to the next. They play central roles in learning, memory, and nearly every function of the nervous system.
How AMPA Receptors Work
AMPA receptors belong to a family called ionotropic glutamate receptors. They sit on the surface of neurons at connection points called synapses, waiting for glutamate, the brain’s main excitatory chemical messenger. When glutamate lands on an AMPA receptor, it triggers the receptor to open a tiny channel in the cell membrane. Sodium ions rush in, creating a quick electrical charge that activates the neuron.
This entire process, from glutamate binding to channel opening, happens in under a millisecond. The channel then closes and resets on a millisecond timescale as well. That speed is what makes AMPA receptors responsible for fast, moment-to-moment brain signaling. Every time you move a muscle, recognize a face, or form a thought, AMPA receptors are firing in rapid sequence across billions of synapses.
What AMPA Receptors Are Made Of
Each AMPA receptor is built from four protein subunits that fit together like puzzle pieces. These subunits come in four varieties: GluA1, GluA2, GluA3, and GluA4. The specific combination determines how the receptor behaves. Most AMPA receptors in the adult brain are pairs of pairs, with GluA1/GluA2 or GluA2/GluA3 being the most common arrangements.
The GluA2 subunit is particularly important because it controls whether calcium can flow through the channel. The vast majority of AMPA receptors contain a modified version of GluA2 that blocks calcium entry, allowing only sodium through. This modification happens through a process called RNA editing, where the cell changes a single building block in the GluA2 protein from glutamine to arginine. That one-amino-acid swap is enough to shut calcium out of the channel almost entirely.
AMPA receptors that lack GluA2, or contain the unedited version, let calcium flood in along with sodium. These calcium-permeable versions are rarer but serve specialized roles. In the inner ear, for instance, receptors built mainly from GluA3 and GluA4 subunits allow calcium entry and are essential for transmitting sound signals at the high speeds hearing requires.
The Role in Learning and Memory
Your brain strengthens or weakens connections between neurons based on experience, and AMPA receptors are the primary mechanism for this. When a connection needs to become stronger (a process called long-term potentiation, or LTP), additional AMPA receptors are physically inserted into the synapse. More receptors means a bigger electrical response to the same amount of glutamate, effectively turning up the volume on that particular neural connection. LTP is widely considered the cellular basis of learning and memory formation.
The reverse also happens. When a connection needs to weaken (long-term depression, or LTD), AMPA receptors are pulled back inside the cell. Fewer receptors means a weaker signal. This two-way trafficking of receptors, adding them to strengthen connections and removing them to weaken connections, is how the brain physically encodes new information and lets old patterns fade.
AMPA vs. NMDA Receptors
AMPA receptors often get mentioned alongside NMDA receptors, and the two work as partners at most synapses. The key difference is speed. AMPA receptors open almost instantly and produce brief electrical currents. NMDA receptor currents last up to ten times longer, sometimes hundreds of milliseconds, and they activate with a slight delay of about 4 to 9 milliseconds after AMPA receptors fire.
NMDA receptors also have a unique quirk: they’re blocked by magnesium at rest. The quick electrical jolt from AMPA receptors is what clears that magnesium block and allows NMDA receptors to open. So in practice, AMPA receptors act as the first responders that kick off signaling, and NMDA receptors extend and amplify it. NMDA receptors are voltage-dependent, meaning they respond differently depending on how electrically active the neuron already is. AMPA receptors are not, making them more straightforward signal carriers.
When AMPA Receptors Cause Damage
Because AMPA receptors control the flow of charged particles into neurons, overactivation can be dangerous. During a stroke, for example, dying cells release massive amounts of glutamate into the surrounding tissue. This floods nearby AMPA receptors with signal, keeping ion channels open far longer than normal. The result is a process called excitotoxicity: neurons become fatally overloaded with calcium and sodium.
Calcium-permeable AMPA receptors (those lacking the GluA2 subunit) are especially implicated in this kind of damage. Sustained calcium influx triggers a cascade of destructive processes inside the cell that leads to neuronal death. This mechanism has been linked to the progression of several neurodegenerative conditions, including ALS and epilepsy, in addition to the acute brain damage seen in stroke.
Anti-AMPA Receptor Encephalitis
In rare cases, the immune system produces antibodies that attack AMPA receptors directly. This condition, called anti-AMPA receptor encephalitis, causes the brain to malfunction as its primary signaling receptors are disrupted. In a review of 55 documented cases, the average patient age was 53, and women were affected roughly twice as often as men.
The most common symptoms were memory loss (reported in 29 of 55 cases), confusion (27 cases), and psychiatric symptoms like mood changes or hallucinations (26 cases). Seizures occurred in about a third of patients. Brain MRI scans were abnormal in 86% of cases, most often showing inflammation in both temporal lobes, the brain regions most involved in memory. Psychiatric symptoms at the time of diagnosis were more common in younger patients, and both memory loss and psychiatric complaints were associated with longer delays before receiving a correct diagnosis.
Medications That Target AMPA Receptors
The clearest example of AMPA-targeted medicine is perampanel, an epilepsy drug that works by blocking AMPA receptors. Rather than competing with glutamate for the receptor’s binding site, perampanel attaches to a different spot on the receptor and prevents the channel from opening properly. This reduces the excessive neural firing that causes seizures.
Perampanel is approved as an add-on treatment for partial-onset seizures in people aged 12 and older. Because glutamate-driven overexcitation is involved in many neurological conditions, AMPA receptors remain a target of significant interest for developing treatments beyond epilepsy, particularly for conditions involving excitotoxicity like stroke and neurodegenerative disease.